Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2003 1
2004 1
2005 3
2008 1
2010 6
2011 3
2012 5
2013 9
2014 5
2015 7
2016 7
2017 3
2018 9
2019 12
2020 9
2021 5
2022 2
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W. Ghia P, et al. Among authors: lysak d. Hemasphere. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36398134 Free PMC article.
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. Ghia P, et al. Among authors: lysak d. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27. J Clin Oncol. 2020. PMID: 32459600 Clinical Trial.
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Kantarjian HM, et al. Among authors: lysak d. J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11. J Clin Oncol. 2012. PMID: 22689805 Free PMC article. Clinical Trial.
Progress in Hematopoietic Stem Cell Transplantation and Cellular Therapies.
Cenariu D, Bumbea H, Colita A, Constantinescu C, Desmirean M, Iluta S, Lysák D, Mussetti A, Tichil I, Tanase A, Tomuleasa C. Cenariu D, et al. Among authors: lysak d. J Clin Med. 2022 Dec 10;11(24):7354. doi: 10.3390/jcm11247354. J Clin Med. 2022. PMID: 36555970 Free PMC article.
NMR spectroscopy of wastewater: A review, case study, and future potential.
Anaraki MT, Lysak DH, Downey K, Kock FVC, You X, Majumdar RD, Barison A, Lião LM, Ferreira AG, Decker V, Goerling B, Spraul M, Godejohann M, Helm PA, Kleywegt S, Jobst K, Soong R, Simpson MJ, Simpson AJ. Anaraki MT, et al. Among authors: lysak dh. Prog Nucl Magn Reson Spectrosc. 2021 Oct-Dec;126-127:121-180. doi: 10.1016/j.pnmrs.2021.08.001. Epub 2021 Aug 19. Prog Nucl Magn Reson Spectrosc. 2021. PMID: 34852923 Review.
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.
Holicek P, Truxova I, Rakova J, Salek C, Hensler M, Kovar M, Reinis M, Mikyskova R, Pasulka J, Vosahlikova S, Remesova H, Valentova I, Lysak D, Holubova M, Kaspar P, Prochazka J, Kasikova L, Spisek R, Galluzzi L, Fucikova J. Holicek P, et al. Among authors: lysak d. Cell Death Dis. 2023 Mar 24;14(3):209. doi: 10.1038/s41419-023-05728-w. Cell Death Dis. 2023. PMID: 36964168 Free PMC article.
Mesenchymal stem cells as the near future of cardiology medicine - truth or wish?
Brychtova M, Thiele JA, Lysak D, Holubova M, Kralickova M, Vistejnova L. Brychtova M, et al. Among authors: lysak d. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Feb;163(1):8-18. doi: 10.5507/bp.2018.071. Epub 2018 Nov 15. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019. PMID: 30439932 Free article. Review.
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, Panovská A, Mašlejová S, Bezděková L, Écsiová D, Vodárek P, Zuchnická J, Mihályová J, Urbanová R, Turcsányi P, Lysák D, Novák J, Brejcha M, Líkařová T, Vodička P, Baranová J, Trněný M, Doubek M; Czech CLL Study Group. Špaček M, et al. Among authors: lysak d. Br J Haematol. 2023 Jul;202(1):40-47. doi: 10.1111/bjh.18736. Epub 2023 Mar 27. Br J Haematol. 2023. PMID: 36971061
93 results